Korean Biotech Talks About U.S. Company Launch

June 29, 2018
Michelle Maskaly
Michelle Maskaly

Michelle Maskaly is Pharmaceutical Executive's Senior Editor. Follow her on Twitter @mmaskaly or email her at michelle.maskaly@ubm.com

Pharmaceutical Executive

Enzychem Lifesciences explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

Enzychem Lifesciences’ Chairman and CEO, Ki-Young Sohn explains why the Korean biotech decided to open U.S. headquarters, as well as gives an update on their most recent clinical trials.

He spoke to Pharm Exec during a company event in New York City.

 

 

 

Related Content:

Global | Pharm Exec Video